FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
|Articles|June 29, 2015
Dr. Maxwell on the Need to Personalize the Treatment of Breast Cancer
Author(s)Kara Maxwell, MD, PhD
Kara Maxwell, MD, PhD, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, discusses the need to personalize the treatment of breast cancer.
Advertisement
Kara Maxwell, MD, PhD, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, discusses the need to personalize the treatment of breast cancer.
Advertisement
Related to this article
Oncology clinicians must actively champion NCCN guidelines as a critical pillar of breast cancer survivorship care,
FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
Patients often use AI to read test results, but AI can misinterpret data and cause panic. Learn why human context remains critical.
Co-developed by NYU Langone and Dana-Farber, the Solavia platform integrates EHR workflows, decision support, and pathway tracking for APPs and PAs.
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
Oncology nursing teams must navigate the clinical logistics and patient education for the newly approved, ctDNA-guided agent camizestrant.
Oncology navigator Emily Beard shares insights on advocacy, the Young Survival Coalition, and dancing to sustain her career.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated, ER-Positive, HER2-Negative Advanced Breast Cancer
2
Prostate Cancer Care: ADT Management and APP Guidance
3
Gynecologic Cancer Awareness: Dr. Teplinsky Discusses Nursing Roles
4
WCLC 2026: Oncology Nursing Takeaways on Supportive Care and APP-Led Models
5